Perioral Blistering and Crusting

Primary Viewpoints: Immunizations with Dr Steven P. Furr

An FDA decision on GSK's Shingrix application is expected by June 20, 2025.

Keith A. Reynolds

October 1st 2024

Vertex on the Verge of Breakthrough for Nonopioid Pain Management as NOPAIN Act Takes Effect

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

October 25th 2023

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Women Show Higher Genetic Predisposition to PTSD: Daily Dose

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

FDA Reviewing New Prefilled Syringe Formulation for GSK’s Shingrix

Your daily dose of the clinical news you may have missed.

Related Content

Patient Care Staff

Primary Viewpoints: Immunizations with Dr Steven P. Furr

An FDA decision on GSK's Shingrix application is expected by June 20, 2025.

Keith A. Reynolds

October 1st 2024

Vertex on the Verge of Breakthrough for Nonopioid Pain Management as NOPAIN Act Takes Effect

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

October 25th 2023

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Women Show Higher Genetic Predisposition to PTSD: Daily Dose

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.